DaVita Retained Earnings (Accumulated Deficit) 2010-2025 | DVA
DaVita retained earnings (accumulated deficit) from 2010 to 2025. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- DaVita retained earnings (accumulated deficit) for the quarter ending March 31, 2025 were $1.698B, a 102.59% increase year-over-year.
- DaVita retained earnings (accumulated deficit) for 2024 were $1.535B, a 156.5% increase from 2023.
- DaVita retained earnings (accumulated deficit) for 2023 were $0.598B, a 242.88% increase from 2022.
- DaVita retained earnings (accumulated deficit) for 2022 were $0.174B, a 50.76% decline from 2021.
DaVita Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024 |
$1,535 |
| 2023 |
$598 |
| 2022 |
$174 |
| 2021 |
$354 |
| 2020 |
$853 |
| 2019 |
$1,432 |
| 2018 |
$2,743 |
| 2017 |
$3,634 |
| 2016 |
$3,710 |
| 2015 |
$4,357 |
| 2014 |
$4,087 |
| 2013 |
$3,364 |
| 2012 |
$3,732 |
| 2011 |
$3,196 |
| 2010 |
$2,718 |
| 2009 |
$2,312 |
DaVita Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2025-03-31 |
$1,698 |
| 2024-12-31 |
$1,535 |
| 2024-09-30 |
$1,275 |
| 2024-06-30 |
$1,061 |
| 2024-03-31 |
$838 |
| 2023-12-31 |
$598 |
| 2023-09-30 |
$715 |
| 2023-06-30 |
$469 |
| 2023-03-31 |
$290 |
| 2022-12-31 |
$174 |
| 2022-09-30 |
$847 |
| 2022-06-30 |
$741 |
| 2022-03-31 |
$516 |
| 2021-12-31 |
$354 |
| 2021-09-30 |
$1,644 |
| 2021-06-30 |
$1,384 |
| 2021-03-31 |
$1,090 |
| 2020-12-31 |
$853 |
| 2020-09-30 |
$2,032 |
| 2020-06-30 |
$1,873 |
| 2020-03-31 |
$1,671 |
| 2019-12-31 |
$1,432 |
| 2019-09-30 |
$3,349 |
| 2019-06-30 |
$3,206 |
| 2019-03-31 |
$2,932 |
| 2018-12-31 |
$2,743 |
| 2018-09-30 |
$3,951 |
| 2018-06-30 |
$4,088 |
| 2018-03-31 |
$3,821 |
| 2017-12-31 |
$3,634 |
| 2017-09-30 |
$4,071 |
| 2017-06-30 |
$4,285 |
| 2017-03-31 |
$4,158 |
| 2016-12-31 |
$3,710 |
| 2016-09-30 |
$5,079 |
| 2016-06-30 |
$4,508 |
| 2016-03-31 |
$4,454 |
| 2015-12-31 |
$4,357 |
| 2015-09-30 |
$4,363 |
| 2015-06-30 |
$4,147 |
| 2015-03-31 |
$3,976 |
| 2014-12-31 |
$4,087 |
| 2014-09-30 |
$3,879 |
| 2014-06-30 |
$3,695 |
| 2014-03-31 |
$3,547 |
| 2013-12-31 |
$3,364 |
| 2013-09-30 |
$3,152 |
| 2013-06-30 |
$4,016 |
| 2013-03-31 |
$3,762 |
| 2012-12-31 |
$3,732 |
| 2012-09-30 |
$3,576 |
| 2012-06-30 |
$3,431 |
| 2012-03-31 |
$3,336 |
| 2011-12-31 |
$3,196 |
| 2011-09-30 |
$3,048 |
| 2011-06-30 |
$2,912 |
| 2011-03-31 |
$2,812 |
| 2010-12-31 |
$2,718 |
| 2010-09-30 |
$2,649 |
| 2010-06-30 |
$2,529 |
| 2010-03-31 |
$2,422 |
| 2009-12-31 |
$2,312 |
| 2009-09-30 |
$2,202 |
| 2009-06-30 |
$2,091 |
| 2009-03-31 |
$1,986 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$10.696B |
$12.816B |
|
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
|
